RxDoctor Payments Data

Steven Emmons, MD

Hematology & Oncology · Montrose, CONPI 1255397782

Payments from drug & device makers

$43,183in general payments, 2019–2025

Across 21 payments — averaging $2056.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$30K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Astrazeneca UK Limited$4K
  • Genentech, Inc.$283
  • Sumitomo Pharma America, Inc.$32
  • Johnson & Johnson$30
  • plus $76 from 5 others

What the payments were for

  • Food & beverage$12791%
  • Education$129%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$43,183 in reported general payments places this provider in the 55th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$105,721
Medicare patients
167
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide26$575,945
VerzenioAbemaciclib23$314,776
XtandiEnzalutamide25$310,405
CalquenceAcalabrutinib Maleate18$275,447
TabrectaCapmatinib Hydrochloride12$268,222
RevlimidLenalidomide15$239,495
Lenalidomide15$214,640
MekinistTrametinib Dimethyl Sulfoxide11$177,989
LumakrasSotorasib12$79,649
Abiraterone Acetate23$45,597
OrgovyxRelugolix15$40,285
EliquisApixaban36$37,339
Hydroxyurea30$1,247
Anastrozole38$766
Dexamethasone32$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$9,482$575,94526 claims
Astellas Pharma US IncXtandi$17$310,40525 claims
AstraZenecaCalquence$29,705$275,44718 claims
Bristol Myers SquibbRevlimid$19$239,49515 claims
Sumitomo Pharma America, Inc.Orgovyx$32$40,28515 claims
PfizerEliquis$12$37,33936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 169 hematology & oncology providers in Colorado.

Other hematology & oncology in Montrose

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →